Neurogene (NGNE) reported second quarter 2026 financial results and recent updates for its NGN-401 gene therapy program for Rett syndrome. The company posted a net loss of $34.5 million for the three months ended June 30, 2026, compared with $22.0 million a year earlier.
Neurogene said Phase 1/2 data for NGN-401 showed 100% of participants improved on the CGI-I scale and gained at least one developmental milestone as of a June 16, 2026 data cutoff. The company also said it extended its cash runway into the first quarter of 2029 after an oversubscribed financing of approximately $144 million in gross proceeds.
- Cash, cash equivalents and short-term investments were $225.4 million as of June 30, 2026.
- Pro forma cash, cash equivalents and short-term investments were approximately $360.2 million, including about $134.8 million of net proceeds from the July 2, 2026 public offering.
- R&D expenses were $25.5 million for the quarter, compared with $19.4 million in the prior-year period.
- G&A expenses were $11.2 million, compared with $6.7 million a year earlier.
- Topline data from the Embolden registrational trial are anticipated in the second half of 2027.
- Neurogene initiated a PPQ campaign in July 2026 to support a planned BLA submission, with completion of PPQ runs expected by the end of 2026.
$NGNE Insider Trading Activity
$NGNE insiders have traded $NGNE stock on the open market 14 times in the past 6 months. Of those trades, 0 have been purchases and 14 have been sales.
Here’s a breakdown of recent trading of $NGNE stock by insiders over the last 6 months:
- CHRISTINE MIKAIL CVIJIC (President and CFO) has made 0 purchases and 9 sales selling 16,203 shares for an estimated $479,454.
- STUART COBB (Chief Scientific Officer) has made 0 purchases and 3 sales selling 6,797 shares for an estimated $141,445.
- RACHEL MCMINN (Chief Executive Officer) sold 3,352 shares for an estimated $73,995
- JULIE JORDAN (Chief Medical Officer) sold 828 shares for an estimated $18,127
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$NGNE Hedge Fund Activity
We have seen 51 institutional investors add shares of $NGNE stock to their portfolio, and 32 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 252,318 shares (+193.6%) to their portfolio in Q1 2026, for an estimated $5,086,730
- LOGOS GLOBAL MANAGEMENT LP removed 195,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $3,931,200
- MILLENNIUM MANAGEMENT LLC added 133,488 shares (+187.2%) to their portfolio in Q1 2026, for an estimated $2,691,118
- CASDIN CAPITAL, LLC added 125,000 shares (+9.6%) to their portfolio in Q1 2026, for an estimated $2,520,000
- BALYASNY ASSET MANAGEMENT L.P. added 109,811 shares (+18.0%) to their portfolio in Q1 2026, for an estimated $2,213,789
- STATE STREET CORP removed 88,683 shares (-28.3%) from their portfolio in Q2 2026, for an estimated $2,789,080
- MORGAN STANLEY removed 85,935 shares (-23.2%) from their portfolio in Q1 2026, for an estimated $1,732,449
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
